Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Seeking Alpha11/6/2026Neutral
ANIK
Anika Therapeutics IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$194.72M
P/E Ratio
—
EPS
$-0.23
Beta
0.20
52W High
$22.88
52W Low
$9.01
50-Day MA
$20.38
200-Day MA
$16.30
Dividend Yield
—
Profit Margin
-3.14%
Forward P/E
20.33
PEG Ratio
2.03
About Anika Therapeutics Inc
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Fundamentals
| Revenue (TTM) | $120.65M |
| Gross Profit (TTM) | $75.00M |
| EBITDA | $3.04M |
| Operating Margin | 11.40% |
| Return on Equity | -2.19% |
| Return on Assets | -0.87% |
| Revenue/Share (TTM) | $8.69 |
| Book Value | $10.33 |
| Price-to-Book | 1.88 |
| Price-to-Sales (TTM) | 1.61 |
| EV/Revenue | 2.031 |
| EV/EBITDA | 478.51 |
| Quarterly Earnings Growth (YoY) | -50.50% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $13.38M |
| Float | $11.29M |
| % Insiders | 6.40% |
| % Institutions | 93.48% |
Historical Volatility
HV 10-Day
148.32%
HV 20-Day
111.71%
HV 30-Day
93.19%
HV 60-Day
67.83%
HV Rank
100.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($23.00 target)
1
Strong Buy1
BuyLatest News
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.
MarketBeat11/6/2026Negative
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.
Zacks Investment Research11/6/2026Positive
Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
GlobeNewsWire11/6/2026Neutral
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
GlobeNewsWire10/22/2026Neutral
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Zacks Investment Research9/25/2026Positive
Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Zacks Investment Research8/26/2026Positive
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research8/24/2026Positive
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Zacks Investment Research8/21/2026Positive
5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
Zacks Investment Research8/19/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANIK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026